Special Issue "Molecular and Cellular Mechanisms of Cancers: Cutaneous Melanoma"
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 30 November 2020.
Interests: Tumor microenvironment; signal transduction pathway activations; cutaneous melanoma; liquid biopsy; epigenetics; biomarkers
Interests: cancer; epigenetics; miRNA; bioinformatics; molecular biology; biotechnology
Cutaneous melanoma (CM) represents one of the most aggressive types of cancer because of its high metastatic power. Several environmental risk factors have been recognized for the development of CM, as well as different molecular mechanisms responsible for the malignant transformation of melanocytes. Notably, the alteration of the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signal transduction pathways are key mechanisms involved in the development of CM, but a growing body of evidence has demonstrated that epigenetic alterations and tumor microenvironment modifications may promote melanoma development and progression. These findings have led to the development of new targeted therapies that ameliorate the overall survival of melanoma patients; however, the mortality rate of CM still remains high due to the development of drug resistance mechanisms.
Therefore, the identification of the molecular mechanisms responsible for therapeutic failure is one of the main goals for the treatment of cutaneous melanomas. Furthermore, the study of epigenetic alterations and tumor microenvironment modifications in patients with melanoma could provide useful information to identify new therapeutic targets and find new early diagnostic and prognostic biomarkers for CM.
On these bases, the focus of this Special Issue will be the evaluation of the molecular and cellular mechanisms involved in melanoma development, progression, aggressiveness, and drug resistance in order to provide updated information about the current status of molecular, pharmaceutical and translational scientific discoveries in the field of Cutaneous Melanoma.
Potential topics will include but are not limited to:
- Environmental and occupational risk factors for cutaneous melanoma;
- Epigenetics modifications and cutaneous melanoma development and progression;
- Novel biomarkers for the early diagnosis of cutaneous melanoma;
- Molecular alterations associated with cutaneous melanoma;
- Tumor microenvironment and matrix metalloproteinases in cutaneous melanoma: Roles and clinical implications;
- Therapeutic strategies for cutaneous melanoma;
- Natural compounds as novel therapeutic strategies;
- Molecular mechanisms and strategies to overcome drug resistance in cutaneous melanoma.
We look forward to your contributions.
Prof. Massimo Libra
Dr. Luca Falzone
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cutaneous melanoma
- targeted therapy
- drug resistance
- RAF and PI3K pathways